The frequency of the predominant Jewish mutations in BRCA1 and BRCA2 in unselected Ashkenazi colorectal cancer patients by Chen-Shtoyerman, R et al.
The co-occurrence of breast cancer (BC) and colorectal cancer
(CRC) has previously been documented (Phipps and Perry, 1989;
Ford et al, 1994; Schoen et al, 1994; Slattery and Kerber, 1994;
Olsen et al, 1999). Women with a history of BC were found to
have an increased risk for developing subsequent CRC (Rozen et
al, 1986; Schoen et al, 1994). Such an association between BC and
CRC could arise due to a genetic predisposition (Slattery and
Kerber, 1994; Stoll, 1998). Several lines of evidence point to a
possible contribution of mutations within the inherited BC suscep-
tibility gene, BRCA1, to CRC pathogenesis: allelic losses at the
BRCA1 locus, putatively targeting this tumour suppressor gene,
have been detected in almost 50% of sporadic CRCs (Garcia-
Patino et al, 1998); Individuals within BRCA1-linked families
have an increased risk for developing CRC – the relative risk of
BRCA1 mutation carriers (by haplotype analysis) for CRC was
found to be 4.11 (Ford et al, 1994) and the risk for developing
CRC in relatives of familial BC patients is increased over that of
the general population (Phipps and Perry, 1989; Slattery and
Kerber, 1994; Burke et al, 1997; Olsen et al, 1999). However, the
increased risk for developing CRC in patients with familial BC is
not uniformly reported by all investigators (Anderson and
Badzioch, 1993; Lin et al, 1999). A high carrier rate of BRCA1/2
families in a defined population permits a comparison of mutation
frequencies between affected CRC individuals and the general
population. 
Among Ashkenazi (East European) Jews, three mutations in the
BRCA1 and BRCA2 genes, account for the majority of inherited
BC predisposition: 185delAG and 5382insC (BRCA1) and
6174delT (BRCA2). Furthermore, these mutations occur at a rate
of about 2.5% among the general Jewish Ashkenazi population
(Struewing et al, 1995, 1997; Roa et al, 1996; Fodor et al, 1998).
These facts and the lack of conclusive evidence for an increased
CRC risk in BC families, prompted us to directly analyse the rel-
ative contribution of these mutations to the pathogenesis of CRC
in Ashkenazi Jews. 
MATERIALS AND METHODS 
Subjects 
225 consecutive Ashkenazi CRC patients were included in the
study: 125 men and 100 women. The patients were diagnosed at
the Sheba and Rabin Medical Centers and had pathologically
confirmed tumours. The Ashkenazi descent was ascertained at least
three generations back. The mean age at diagnosis was 65.3 ± 17.2
years, and the mean age at the time of study was 73.5 ± 11.0 years. 
The study was approved by the Institutional Review Board at
both medical centres. All participants signed a written informed
consent, and a detailed questionnaire, with special emphasis on
cancer family history was filled out. 
Molecular analysis 
DNA was extracted from peripheral blood leukocytes using stand-
ard techniques and analysis for the three predominant mutations
was performed using PCR and restriction fragment length poly-
morphism, as previously described (Rohlfs et al, 1997) and
adopted by us (Bruchim Bar-Sade et al, 1998). 
Statistical analysis 
Carrier frequency rates were compared between the CRC study
group and published data regarding the general Ashkenazi popula-
tion, using Fisher’s Exact Test. 
RESULTS 
Overall, 4 out of the 225 patients tested (1.78%) were
BRCA1/BRCA2 mutation carriers. The carriers consisted of two
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males and two females. One male patient was a 185delAG BRCA1
mutation carrier (0.44%) and the other male a 5382insC BRCA1
mutation carrier (0.44%). The two female patients (0.88%)
harboured the 6174delT BRCA2 mutation. Of note, 3 out of the 4
mutation carriers had either a personal or family history of BC.
The relevant clinical data of these carrier individuals are shown in
Table 1. The differences between the mutation carrier frequencies
in this patient population were not statistically significant
compared with those of the general population (Struewing et al,
1997), as calculated using Fisher’s Exact Test (Table 2). 
Among the remaining 98 non-carrier females with CRC, only
one patient (1.02%) had a primary diagnosis of BC at age 52 years
and a diagnosis of CRC 18 years later. 13 out of the 131 (9.92%)
CRC patients, who completed the family history questionnaire,
reported BC in a first degree family member. This rate is in
concordance with the rates of BC in the general Jewish population
(Bar-Chana et al, 1996). 
DISCUSSION 
Previous analysis of the three common Jewish BRCA1/2 germline
mutations in a large, unselected group of Jewish Asheknazi indi-
viduals did not find an increased risk for developing CRC among
mutation carriers (Struewing et al, 1997). Lin et al reported that
the lifetime risk for CRC in 32 American BRCA1/2 families was
similar to the risk in the general population (1999). Our results
support these data by analysis of unselected CRC patients, and
complement previous studies performed on individuals from high-
risk families. Of note, had we excluded patients with personal or
familial history of BC from the patient cohort as well as from the
control group analysed, the lack of association between these
mutations and CRC would be even more striking. Taken together
with the recent publications showing these specific mutations do
not increase the risk for prostate cancer in this ethnic group
(Lehrer et al, 1998; Hubert et al, 1999; Vazina et al, 2000), we can
conclude that the predominant Ashkenazi Jewish BRCA1 and
BRCA2 mutations do not contribute to the pathogenesis of CRC.
Thus, it seems that the two major indications for performing
BRCA1/2 genetic testing in men are the personal risk for
developing BC (Struewing et al, 1999) and the risk of transmitting
the mutated alleles to their daughters. 
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